Overview
Pfizer Limited, a subsidiary of the global pharmaceutical giant Pfizer Inc., is a prominent player in the Indian healthcare industry. Established in 1950, Pfizer Limited operates across various therapeutic areas, offering a diverse portfolio of prescription medicines, vaccines, and consumer healthcare products. The Company has a portfolio of over 150 products across 15 therapeutic areas. Its top brands include Prevenar 13, Corex – DX, Dolonex, Enbrel, Becosules and Folvite among others. In addition to its commercial operations, Pfizer Limited also operates a state-of-the-art, award-winning manufacturing facility in Goa.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Pfizer Inc. as of June 29, 2025 is 63,833.00 MM.
- The operating income for Pfizer Inc. as of June 29, 2025 is 17,735.00 MM.
- The net income for Pfizer Inc. as of June 29, 2025 is 10,752.00 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-29 | 63,833.00 | 17,735.00 | 10,752.00 |
| 2025-03-30 | 62,464.00 | 16,445.00 | 7,883.00 |
| 2024-12-31 | 63,627.00 | 16,328.00 | 8,031.00 |
| 2024-09-29 | 60,433.00 | 18,748.00 | 4,252.00 |
| 2024-06-30 | 56,224.00 | 10,537.00 | -2,595.00 |
| 2024-03-31 | 55,947.00 | 10,358.00 | -309.00 |
| 2023-12-31 | 59,554.00 | 12,517.00 | 2,119.00 |
| 2023-10-01 | 69,274.00 | 13,498.00 | 10,482.00 |
| 2023-07-02 | 78,420.00 | 26,018.00 | 21,473.00 |
| 2023-04-02 | 93,154.00 | 35,512.00 | 29,051.00 |
| 2022-12-31 | 101,175.00 | 39,841.00 | 31,372.00 |
| 2022-10-02 | 99,878.00 | 39,525.00 | 29,771.00 |
| 2022-07-03 | 101,275.00 | 38,210.00 | 29,308.00 |
| 2022-04-03 | 92,433.00 | 32,167.00 | 24,966.00 |
| 2021-12-31 | 81,288.00 | 26,980.00 | 21,979.00 |
| 2021-10-03 | 68,877.00 | 22,024.00 | 19,432.00 |
| 2021-07-04 | 55,119.00 | 14,720.00 | 12,756.00 |
| 2021-04-04 | 46,084.00 | 11,514.00 | 10,681.00 |
| 2020-12-31 | 41,651.00 | 9,791.00 | 9,159.00 |
| 2020-09-27 | 32,334.00 | 3,466.00 | 7,977.00 |
Income Statement: EPS
- The earnings per share basic for Pfizer Inc. as of June 29, 2025 is 1.90.
- The earnings per share diluted for Pfizer Inc. as of June 29, 2025 is 1.89.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-29 | 1.90 | 1.89 |
| 2025-03-30 | 1.39 | 1.38 |
| 2024-12-31 | 1.42 | 1.41 |
| 2024-09-29 | 0.75 | 0.74 |
| 2024-06-30 | -0.46 | -0.47 |
| 2024-03-31 | -0.05 | -0.06 |
| 2023-12-31 | 0.38 | 0.37 |
| 2023-10-01 | 1.86 | 1.84 |
| 2023-07-02 | 3.82 | 3.76 |
| 2023-04-02 | 5.18 | 5.07 |
| 2022-12-31 | 5.59 | 5.47 |
| 2022-10-02 | 5.31 | 5.19 |
| 2022-07-03 | 5.23 | 5.11 |
| 2022-04-03 | 4.45 | 4.36 |
| 2021-12-31 | 3.92 | 3.85 |
| 2021-10-03 | 3.48 | 3.43 |
| 2021-07-04 | 2.29 | 2.26 |
| 2021-04-04 | 1.92 | 1.89 |
| 2020-12-31 | 1.65 | 1.63 |
| 2020-09-27 | 1.44 | 1.41 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Pfizer Inc. as of June 29, 2025 is 15,188.00 MM.
- The cash from investing activities for Pfizer Inc. as of June 29, 2025 is 3,545.00 MM.
- The cash from financing activities for Pfizer Inc. as of June 29, 2025 is -18,173.00 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-29 | 15,188.00 | 3,545.00 | -18,173.00 |
| 2025-03-30 | 13,989.00 | 4,194.00 | -17,436.00 |
| 2024-12-31 | 12,744.00 | 2,652.00 | -17,140.00 |
| 2024-09-29 | 11,263.00 | -6,721.00 | -6,584.00 |
| 2024-06-30 | 8,005.00 | -3,776.00 | -5,727.00 |
| 2024-03-31 | 8,578.00 | -33,861.00 | 23,906.00 |
| 2023-12-31 | 8,700.00 | -32,278.00 | 26,066.00 |
| 2023-10-01 | 12,042.00 | -25,692.00 | 15,609.00 |
| 2023-07-02 | 14,560.00 | -27,207.00 | 13,627.00 |
| 2023-04-02 | 23,938.00 | -13,035.00 | -11,027.00 |
| 2022-12-31 | 29,267.00 | -15,783.00 | -14,834.00 |
| 2022-10-02 | 26,599.00 | -13,959.00 | -13,170.00 |
| 2022-07-03 | 31,454.00 | -23,408.00 | -8,510.00 |
| 2022-04-03 | 34,583.00 | -20,232.00 | -13,587.00 |
| 2021-12-31 | 32,580.00 | -22,546.00 | -9,816.00 |
| 2021-10-03 | 32,291.00 | -11,630.00 | -20,252.00 |
| 2021-07-04 | 23,552.00 | -1,073.00 | -21,972.00 |
| 2021-04-04 | 15,808.00 | -5,947.00 | -10,256.00 |
| 2020-12-31 | 14,403.00 | -4,271.00 | -9,649.00 |
| 2020-09-27 | 12,547.00 | -15,434.00 | 1,698.00 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/e for Pfizer Inc. as of June 29, 2025 is 17.41.
- The p/book for Pfizer Inc. as of June 29, 2025 is 1.55.
- The p/tbv for Pfizer Inc. as of June 29, 2025 is -3.84.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-29 | 17.41 | 1.55 | -3.84 |
| 2025-03-30 | 1.53 | -4.52 | |
| 2024-12-31 | 1.70 | -3.69 | |
| 2024-09-29 | -63.26 | 1.77 | -4.42 |
| 2024-06-30 | -509.81 | 1.76 | -3.68 |
| 2024-03-31 | 74.24 | 1.62 | -4.43 |
| 2023-12-31 | 15.51 | 1.64 | 21.55 |
| 2023-10-01 | 8.72 | 1.85 | 22.69 |
| 2023-07-02 | 7.02 | 2.13 | 83.60 |
| 2023-04-02 | 7.34 | 2.48 | -124.09 |
| 2022-12-31 | 3.29 | 29.13 | |
| 2022-10-02 | 2.98 | 65.98 | |
| 2022-07-03 | 3.79 | -114.47 | |
| 2022-04-03 | 13.19 | 3.82 | 179.86 |
| 2021-12-31 | 16.66 | 4.71 | -60.48 |
| 2021-10-03 | 18.25 | 3.50 | -28.97 |
| 2021-07-04 | 20.05 | ||
| 2021-04-04 | 13.57 | 1.96 | -8.53 |
| 2020-12-31 | 29.26 | 4.22 | -18.39 |
| 2020-09-27 | 8.76 | 1.92 | -4.51 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for Pfizer Inc. as of June 29, 2025 is 0.04.
- The ebit (3y)/ev for Pfizer Inc. as of June 29, 2025 is 0.06.
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-29 | 0.04 | 0.06 |
| 2025-03-30 | 0.04 | 0.07 |
| 2024-12-31 | 0.02 | 0.06 |
| 2024-09-29 | -0.02 | 0.07 |
| 2024-06-30 | -0.01 | 0.08 |
| 2024-03-31 | 0.00 | 0.09 |
| 2023-12-31 | 0.05 | 0.10 |
| 2023-10-01 | 0.09 | 0.09 |
| 2023-07-02 | 0.13 | 0.10 |
| 2023-04-02 | 0.13 | 0.08 |
| 2022-12-31 | 0.10 | 0.06 |
| 2022-10-02 | 0.11 | 0.05 |
| 2022-07-03 | 0.08 | 0.05 |
| 2022-04-03 | 0.07 | 0.05 |
| 2021-12-31 | 0.06 | 0.04 |
| 2021-10-03 | 0.05 | 0.04 |
| 2021-07-04 | ||
| 2021-04-04 | 0.04 | 0.07 |
| 2020-12-31 | 0.02 | 0.03 |
| 2020-09-27 | 0.05 | 0.06 |
Management Effectiveness
- The roa for Pfizer Inc. as of June 29, 2025 is 0.04.
- The roe for Pfizer Inc. as of June 29, 2025 is 0.09.
- The roic for Pfizer Inc. as of June 29, 2025 is 0.05.
- The croic for Pfizer Inc. as of June 29, 2025 is 0.00.
- The ocroic for Pfizer Inc. as of June 29, 2025 is 0.09.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-29 | 0.04 | 0.09 | 0.05 | 0.00 | 0.09 |
| 2025-03-30 | 0.04 | 0.08 | 0.05 | -0.01 | 0.08 |
| 2024-12-31 | 0.02 | 0.04 | 0.03 | -0.01 | 0.07 |
| 2024-09-29 | -0.01 | -0.03 | -0.02 | -0.01 | 0.05 |
| 2024-06-30 | -0.00 | -0.00 | -0.00 | -0.01 | 0.05 |
| 2024-03-31 | 0.01 | 0.02 | 0.01 | 0.01 | 0.05 |
| 2023-12-31 | 0.05 | 0.12 | 0.06 | 0.01 | 0.07 |
| 2023-10-01 | 0.11 | 0.26 | 0.13 | 0.01 | 0.09 |
| 2023-07-02 | 0.16 | 0.38 | 0.21 | -0.00 | 0.18 |
| 2023-04-02 | 0.17 | 0.41 | 0.24 | -0.01 | 0.22 |
| 2022-12-31 | 0.17 | 0.42 | 0.24 | -0.01 | 0.21 |
| 2022-10-02 | 0.17 | 0.43 | 0.24 | -0.00 | 0.26 |
| 2022-07-03 | 0.16 | 0.36 | 0.21 | 0.01 | 0.30 |
| 2022-04-03 | 0.14 | 0.35 | 0.19 | 0.00 | 0.28 |
| 2021-12-31 | 0.13 | 0.30 | 0.19 | 0.00 | 0.29 |
| 2021-10-03 | 0.07 | 0.20 | 0.12 | 0.01 | 0.22 |
| 2021-07-04 | 0.06 | 0.17 | 0.10 | -0.00 | 0.14 |
| 2021-04-04 | 0.06 | 0.14 | 0.09 | 0.00 | 0.14 |
| 2020-12-31 | 0.06 | 0.15 | 0.09 | 0.00 | 0.13 |
| 2020-09-27 | 0.09 | 0.24 | 0.11 | 0.00 | 0.12 |
Gross Margins
- The gross margin for Pfizer Inc. as of June 29, 2025 is 0.74.
- The net margin for Pfizer Inc. as of June 29, 2025 is 0.13.
- The operating margin for Pfizer Inc. as of June 29, 2025 is 0.26.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-29 | 0.74 | 0.13 | 0.26 |
| 2025-03-30 | 0.74 | 0.13 | 0.26 |
| 2024-12-31 | 0.70 | 0.07 | 0.19 |
| 2024-09-29 | 0.60 | -0.05 | 0.06 |
| 2024-06-30 | 0.59 | -0.01 | 0.06 |
| 2024-03-31 | 0.59 | 0.04 | 0.09 |
| 2023-12-31 | 0.62 | 0.15 | 0.19 |
| 2023-10-01 | 0.70 | 0.28 | 0.33 |
| 2023-07-02 | 0.69 | 0.31 | 0.38 |
| 2023-04-02 | 0.66 | 0.31 | 0.39 |
| 2022-12-31 | 0.66 | 0.30 | 0.39 |
| 2022-10-02 | 0.62 | 0.29 | 0.38 |
| 2022-07-03 | 0.61 | 0.27 | 0.35 |
| 2022-04-03 | 0.62 | 0.27 | 0.33 |
| 2021-12-31 | 0.65 | 0.27 | 0.33 |
| 2021-10-03 | 0.71 | 0.24 | 0.27 |
| 2021-07-04 | 0.77 | 0.23 | 0.25 |
| 2021-04-04 | 0.80 | 0.22 | 0.23 |
| 2020-12-31 | 0.22 | 0.23 | |
| 2020-09-27 | 0.80 | 0.39 | 0.19 |
Identifiers and Descriptors
| Central Index Key (CIK) | 78003 |
Industry Groups
| SIC 2834 - Pharmaceutical Preparations |
